Conditions: Chronic Obstructive Pulmonary Disease, COPD
Keywords: Chronic Obstructive Pulmonary Disease, COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 660
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.

Detailed description:

Arms:
arm 1: Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily arm 2: Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily

Interventions: intervention 1: Symbicort (budesonide/formoterol turbuhaler 320/9ug) intervention 2: Spiriva (tiotropium bromide 18ug)
Intervention descriptions: intervention 1: Symbicort (budesonide/formoterol turbuhaler 320/9ug) intervention 2: Spiriva (tiotropium bromide 18ug)

Protocol document: